MarketCap
Facebook
X
Telegram
Tenax Therapeutics Accounts Receivables | TENX
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Tenax Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 1967 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | 50.2 K | 72.6 K | 49.4 K | 36.4 K | 445 K | 13.4 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 445 K | 13.4 K | 111 K |
Quarterly Accounts Receivables Tenax Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 39.3 K | 39.3 K | 50.2 K | 50.2 K | 50.2 K | 50.2 K | 72.6 K | 72.6 K | 72.6 K | 72.6 K | 49.4 K | 49.4 K | 49.4 K | 49.4 K | 53.1 K | 36.4 K | 36.4 K | 36.4 K | 13.6 K | 64.8 K | 96.8 K | 445 K | 19.4 K | 17.2 K | 23.6 K | 13.4 K | - | 7.56 K | 28.1 K | 139 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 445 K | 7.56 K | 62 K |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
12.6 B | $ 263.04 | 0.49 % | $ 465 B |  USA |
 |
AbCellera Biologics
ABCL
|
39.4 M | $ 11.41 | 2.15 % | $ 3.41 B |  Canada |
 |
Aclaris Therapeutics
ACRS
|
318 K | $ 5.53 | 6.02 % | $ 678 M | USA |
 |
ADC Therapeutics SA
ADCT
|
29.1 M | $ 1.09 | 3.74 % | $ 139 M |  Schweiz |
 |
Clovis Oncology
CLVS
|
26.9 M | - | -7.23 % | $ 13 M | USA |
 |
Chimerix
CMRX
|
57 K | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
218 K | - | - | $ 401 M | USA |
 |
ADMA Biologics
ADMA
|
158 M | $ 8.61 | 0.16 % | $ 2.05 B | USA |
 |
Eiger BioPharmaceuticals
EIGR
|
1.68 M | - | -9.21 % | $ 2.55 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
97 K | - | - | $ 384 M |  Britain |
 |
Fusion Pharmaceuticals
FUSN
|
7 K | - | - | $ 1.41 B | Canada |
 |
Guardion Health Sciences
GHSI
|
2.27 M | - | -0.31 % | $ 3.64 M | USA |
 |
G1 Therapeutics
GTHX
|
12.7 M | - | - | $ 370 M | USA |
 |
Humanigen
HGEN
|
44 K | - | -81.12 % | $ 4.28 M | USA |
 |
HOOKIPA Pharma
HOOK
|
290 K | - | -6.92 % | $ 79.4 M | USA |
 |
Intercept Pharmaceuticals
ICPT
|
26.9 M | - | - | $ 643 M | USA |
 |
IGM Biosciences
IGMS
|
800 K | - | - | $ 76.9 M | USA |
 |
Intra-Cellular Therapies
ITCI
|
166 M | - | - | $ 13.6 B | USA |
 |
Chinook Therapeutics
KDNY
|
262 K | - | - | $ 2.6 B | USA |
 |
Karuna Therapeutics
KRTX
|
57 K | - | - | $ 12.2 B | USA |
 |
La Jolla Pharmaceutical Company
LJPC
|
8.61 M | - | - | $ 154 M | USA |
 |
LogicBio Therapeutics
LOGC
|
30 K | - | - | $ 229 M | USA |
 |
Lumos Pharma
LUMO
|
24.5 M | - | - | $ 35.3 M | USA |
 |
Merrimack Pharmaceuticals
MACK
|
100 K | - | - | $ 216 M | USA |
 |
Mirati Therapeutics
MRTX
|
865 K | - | - | $ 3.3 B | USA |
 |
9 Meters Biopharma
NMTR
|
90 K | - | -42.97 % | $ 1.05 M | USA |
 |
Oncternal Therapeutics
ONCT
|
9 K | - | -24.12 % | $ 1.56 M | USA |
 |
Opiant Pharmaceuticals
OPNT
|
13.3 M | - | - | $ 109 M | USA |
 |
Orchard Therapeutics plc
ORTX
|
8.47 M | - | 1.02 % | $ 90.8 M | Britain |